Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: Current update

Expert Opinion on Drug Delivery

Volumn 12, Issue 2, 2015, Pages 339-347

  Soyka, Michael ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Privatklinik Meiringen   (Switzerland)

Author keywords

Buprenorphine; Buprenorphine film; Naloxone; Opioid dependence; Opioids; Pharmacotherapy

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; KETOCONAZOLE; OPIATE; BUPRENORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; TABLET;

ATTENTION DISTURBANCE; BLURRED VISION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; ERYTHEMA; GLOSSODYNIA; HEART PALPITATION; HUMAN; HYPERHIDROSIS; INSOMNIA; LETHARGY; META ANALYSIS (TOPIC); MIOSIS; OPIATE ADDICTION; PLASMA HALF LIFE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; SINGLE DRUG DOSE; VOMITING; WITHDRAWAL SYNDROME; MEDICINAL CHEMISTRY; OPIOID-RELATED DISORDERS; TABLET;

ANALGESICS, OPIOID; BUPRENORPHINE; CHEMISTRY, PHARMACEUTICAL; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; TABLETS;

EID: 84921532442     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.953479     Document Type: Review

References (84)

1. Baumgartner G, Soyka M. DSM-5 - what has changed in therapy for and research on substance-related and addictive disorders?. Fortschr Neurol Psychiatr 2013;81(11):648-54
2. United Nations Office on Drugs and Crime. 2006 World Drug Report. Volume 2 UNODC, United Nations Publication: Vienna; 2006
3. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372(9651):1733-45
4. European Monitoring Centre for Drugs and Drug Addiction. Mortality related to drug use in Europe: Public health implications. EMDCCA; Lisbon: 2011
5. Kessler RC, Avenevoli S, Costello EJ, et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry 2011;69(4):372-80
6. Kleber HD, Weiss RD, Anton RF Jr, et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry 2007;164(4 Suppl):5-123
7. World Health Organization. The World Health Report 2004. World Health Organization; Geneva: 2004
8. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013;382(9904):1564-74
9. Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr 2013;163(5):1377-83.e1-3
10. Soyka M. Buprenorphine use and risk of abuse and diversion. Adv Pharmacoepidemiol Drug Saf 2014;3:1-11
11. Bargagli AM, Hickman M, Davoli M, et al. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006;16(2):198-202
12. Bjornaas MA, Bekken AS, Ojlert A, et al. A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo. BMC Psychiatry 2008;8:8
13. Hser YI, Anglin D, Powers K. A 24-year follow-up of California narcotics addicts. Arch Gen Psychiatry 1993;50(7):577-84
14. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 2004;4(1):39-50
15. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13(5):177-84
16. Koob GF, Le Moal M. Neurobiology of addiction. Academic Press, Amsterdam; 2006
17. Luscher C, Ungless MA. The mechanistic classification of addictive drugs. PLoS Med 2006;3(11):e437 • Landmark paper on the molecular basis of addiction.
18. Schreckenberger M, Klega A, Grunder G, et al. Opioid receptor PET reveals the psychobiologic correlates of reward processing. J Nucl Med 2008;49(8):1257-61
19. Berglund M, Thelander S, Jonsson E. Treating alcohol and drug abuse: an evidence based review. Wiley-VCH, Weinheim; 2003
20. Termorshuizen F, Krol A, Prins M, et al. Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol 2005;161(3):271-9
21. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and metaanalysis of cohort studies. Addiction 2011;106(1):32-51 • Important review.
22. Hulse GK, English DR, Milne E, et al. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999;94(2):221-9
23. Amato L, Davoli M, Perucci CA, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28(4):321-9
24. Bukten A, Skurtveit S, Gossop M, et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction 2012;107(2):393-9
25. Maremmani I, Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010;19(6):557-68
26. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003(2):CD002209
27. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11(9):1-171.iii-iv •• Important review on opioid maintenance therapy.
28. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008(2):CD002207
29. Soyka M, Zingg C, Koller G, et al. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol 2008;11(5):641-53
30. Soyka M, Kranzler HR, van den Brink W, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: opioid dependence. World J Biol Psychiatry 2011;12(3):160-87
31. Wittchen HU, Apelt SM, Soyka M, et al. Feasibility and outcome of substitution treatment of heroindependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 2008;95(3):245-57
32. Winstock AR, Lea T. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Subst Use Misuse 2010;45(1-2):240-52
33. Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy 2008;19(6):450-8
34. Winstock AR, Lea T, Sheridan J. What is diversion of supervised buprenorphine and how common is it? J Addict Dis 2009;28(3):269-78
35. Soyka M. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence. Expert Opin Drug Deliv 2012;9(11):1409-17
36. Orman JS, Keating GM. Buprenorphine/ naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009;69:577-607 • Comprehensive review.
37. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on muopioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28(11):2000-7
38. Greenwald M, Johanson CE, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 2007;61(1):101-10
39. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55(5):569-80
40. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997;54(8):713-20
41. Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007;164(5):797-803
42. Soyka M, Kranzler HR, Berglund M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: alcoholism. World J Biol Psychiatry 2008;9(1):6-23
43. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109:79-87
44. Amato L, Davoli M, Perucci CA, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28:321-9
45. Hanon S, Seewald RM, Yang F, et al. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol 2010;28:19-22
46. McCance-Katz E. Drug-drug interactions in opioid therapy. 7th edition. PCM Healthcare Ltd; London: 2012
47. Centers for Disease Control and Prevention (CDC). Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010;59:705-9
48. Boyer EW, McCance-Katz EF, Marcus S. Methadone and buprenorphine toxicity in children. Am J Addict 2010;19:89-95
49. Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. Pediatrics 2008;121:e782-6
50. van Dorp E, Yassen A, Dahan A. the risks and benefits. Expert Opin Drug Saf 2007;6:125-32
51. Stoller KB, Bigelow GE, Walsh SL, et al. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 2001;154:230-42
52. Ling W, Jacobs P, Hillhouse M, et al. From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat 2010;38(Suppl 1):S53-60
53. Mammen K, Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother 2009;10:2537-44
54. Doolittle B, Becker W. A case series of buprenorphine/naloxone treatment in a primary care practice. Subst Abus 2011;32:262-5
55. Amass L, Pukeleviciene V, Subata E, et al. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addiction 2012;107:142-51
56. New South Wales Department of Health. Opioid treatment program: Clinical guidelines for methadone and buprenorphine treatment. NSW Government, Sydney; 2011
57. Lingford-Hughes AR, Welch S, Peters L, et al. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012;26:899-952
58. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization, Geneva; 2009
59. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939 Substance Abuse and Mental Health Services Administration, Rockville, MD; 2004
60. Canadian Agency for Drugs and Technologies in Health. Suboxone versus Methadone for the treatment of opioid dependence: a review of the clinical and cost-effectiveness [Internet]. Canadian Agency, Ottawa (ON); 2013
61. Mauger S, Fraser R, Gill K. Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat 2014;10:587-98
62. Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev 2011;4:28-41
63. Clay E, Khemiri A, Zah V, et al. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation in adults with opioid dependence. J Med Econ 2014;6:6-11
64. Lintzeris N, Leung SY, Dunlop AJ, et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend 2013;131:119-26
65. Das NG, Das SK. Development of mucoadhesive dosage forms of buprenorphine for sublingual drug delivery. Drug Deliv 2004;11:89-95
66. Compton P, Ling W, Moody D, et al. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend 2006;82:25-31
67. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627-32
68. Pirnay S, Borron SW, Giudicelli CP, et al. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004;99:978-88
69. Food and Drug Administration. Prescribing information for Suboxone. US Food and Drug Administration, Silver Spring, MD; 2014
70. Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics 2011;12:215-33
71. Kobayashi K, Yamamoto T, Chiba T, et al. Human buprenorphine Ndealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1988;26:818-21
72. Moody DE, Slawson MH, Strain EC, et al. A liquid chromatographicelectrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 2002;306:31-9
73. Picard N, Cresteil T, Djebli N, et al. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 2005;33:689-95
74. Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse 2011;37:1-11
75. Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 2002;25:682-5
76. Zhang W, Ramamoorthy Y, Tyndale RF, et al. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos 2003;31:768-72
77. Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 1990;25:27-34
78. Karan LD, McCance-Katz E, Zajicek A. Pharmacokinetics and pharmacodynamic principles. In: Ries RK, Fiellin DA, Miller SC, editors, Principles of addiction medicine. 4th edition. Wolters Kluwer/ Lippincott Williams & Wilkins, Philadelphia; 2009. p. 67-84
79. PCM Scientific. Drug-drug interactions in opioid therapy. A focus on buprenorphine & methadone. 2012. Available from: www.opioiddruginteractions.com [cited 20th May 2014]
80. Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther 2011;89:443-9 •• Important experimental study.
81. Larance B, Lintzeris N, Ali R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend 2014;136:21-7
82. Centers for Disease Control and Prevention (CDC). Buprenorphine prescribing practices and exposures reported to a poison center - Utah, 2002-2011. MMWR Morb Mortal Wkly Rep 2012. 61:997-1001
83. Fischer A, Jonsson M, Hjelmstrom P. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm 2013. [Epub ahead of print]
84. Ling W, Mooney L, Zhao M, et al. Selective review and commentary on emerging pharmacotherapies for opioid addiction. Subst Abuse Rehabil 2011;2:181-8